[go: up one dir, main page]

DOP2010000137A - Derivados de 1,2,3-triazol como inhibidores de estearoil-coenzima a desaturasa - Google Patents

Derivados de 1,2,3-triazol como inhibidores de estearoil-coenzima a desaturasa

Info

Publication number
DOP2010000137A
DOP2010000137A DO2010000137A DO2010000137A DOP2010000137A DO P2010000137 A DOP2010000137 A DO P2010000137A DO 2010000137 A DO2010000137 A DO 2010000137A DO 2010000137 A DO2010000137 A DO 2010000137A DO P2010000137 A DOP2010000137 A DO P2010000137A
Authority
DO
Dominican Republic
Prior art keywords
desaturasa
coenzima
estearoil
inhibitors
triazol derivatives
Prior art date
Application number
DO2010000137A
Other languages
English (en)
Inventor
Anne Marie Jeanne Bouillot
Alain Laroze
Lionel Trottet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of DOP2010000137A publication Critical patent/DOP2010000137A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La presente invención se refiere a compuestos de triazol sustituidos de la formula (I): Y sales farmaceuticamente aceptables de los mismos, a composiciones farmacéuticas que los contienen y a su uso en medicina; en particular, la invención se refiere a compuestos para modular la actividad de SCD.
DO2010000137A 2007-11-09 2010-05-07 Derivados de 1,2,3-triazol como inhibidores de estearoil-coenzima a desaturasa DOP2010000137A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0722077.5A GB0722077D0 (en) 2007-11-09 2007-11-09 Compounds

Publications (1)

Publication Number Publication Date
DOP2010000137A true DOP2010000137A (es) 2010-08-15

Family

ID=38858481

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000137A DOP2010000137A (es) 2007-11-09 2010-05-07 Derivados de 1,2,3-triazol como inhibidores de estearoil-coenzima a desaturasa

Country Status (31)

Country Link
US (2) US8486977B2 (es)
EP (2) EP2207770B1 (es)
JP (1) JP5491407B2 (es)
KR (1) KR101577080B1 (es)
CN (1) CN101918376B (es)
AT (1) ATE512140T1 (es)
AU (1) AU2008324172B2 (es)
BR (1) BRPI0820471A2 (es)
CA (1) CA2705113C (es)
CO (1) CO6270331A2 (es)
CR (1) CR11482A (es)
CY (2) CY1112233T1 (es)
DK (2) DK2207770T3 (es)
DO (1) DOP2010000137A (es)
EA (1) EA016621B1 (es)
ES (2) ES2457521T3 (es)
GB (1) GB0722077D0 (es)
HR (2) HRP20110552T1 (es)
IL (1) IL205152A (es)
MA (1) MA31801B1 (es)
ME (1) ME01962B (es)
MX (1) MX2010005187A (es)
MY (1) MY163126A (es)
NZ (1) NZ584725A (es)
PL (2) PL2368887T3 (es)
PT (2) PT2207770E (es)
RS (2) RS53294B (es)
SI (2) SI2368887T1 (es)
UA (1) UA107324C2 (es)
WO (1) WO2009060053A1 (es)
ZA (1) ZA201002596B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
WO2010030046A1 (en) * 2008-09-15 2010-03-18 Daikin Industries, Ltd. Aqueous polymer dispersion composition and surface treatment agent
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
FR2974089B1 (fr) * 2011-04-18 2014-04-25 Univ Nice Sophia Antipolis Derives de l'acadesine, produits et compositions les comprenant, leurs utilisations therapeutiques et leurs procedes de synthese.
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CA2879176C (en) * 2012-09-17 2020-10-27 F.Hoffmann-La Roche Ag Triazole carboxamide derivatives
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
PL3250563T3 (pl) 2015-01-30 2022-05-02 Neurocrine Biosciences, Inc. Podstawione triazole i dotyczące ich sposoby
KR20180036318A (ko) * 2016-09-30 2018-04-09 경북대학교 산학협력단 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
KR102292989B1 (ko) * 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3784234A1 (en) * 2018-04-25 2021-03-03 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR102017324B1 (ko) * 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN114656414B (zh) * 2022-05-24 2022-08-23 常熟华虞环境科技有限公司 三氮唑改性二氧化钛光催化剂及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US20070087363A1 (en) 1998-12-22 2007-04-19 Myriad Genetics, Incorporated Therapeutic methods, compounds and compositions
PT1315831E (pt) 2000-02-24 2010-11-04 Xenon Pharmaceuticals Inc Estearoil-coa dessaturase para identificar agentes terapêuticos que reduzem triglicéridos
CA2430987A1 (en) 2000-09-26 2002-04-04 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
BRPI0412343A (pt) 2003-07-30 2006-09-05 Xenon Pharmaceuticals Inc derivados de piridazina e seu uso como agentes terapêuticos
KR20060037409A (ko) * 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피페라진 유도체 및 그의 치료제로서의 용도
WO2007046868A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Thiazolidine derivatives and their uses as therapeutic agents
WO2007046867A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
WO2008073461A2 (en) * 2006-12-11 2008-06-19 Wyeth Ion channel modulators
GB0625604D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625654D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625605D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
WO2008104524A1 (en) 2007-02-28 2008-09-04 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
US20100137312A1 (en) * 2007-05-15 2010-06-03 Neurosearch A/S Novel aromatic heterocyclic carboxylic acid amide derivatives useful as potassium channel modulators
GB0714129D0 (en) 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
GB0715055D0 (en) 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
GB0721419D0 (en) 2007-10-31 2007-12-12 Smithkline Beecham Corp Compounds
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0810913D0 (en) 2008-06-13 2008-07-23 Smithkline Beecham Corp Comppounds

Also Published As

Publication number Publication date
EP2207770B1 (en) 2011-06-08
US9051281B2 (en) 2015-06-09
US20130281499A1 (en) 2013-10-24
IL205152A0 (en) 2010-11-30
CA2705113C (en) 2016-01-05
IL205152A (en) 2013-10-31
AU2008324172A1 (en) 2009-05-14
DK2368887T3 (da) 2014-04-14
DK2207770T3 (da) 2011-09-12
KR20100095574A (ko) 2010-08-31
MY163126A (en) 2017-08-15
UA107324C2 (uk) 2014-12-25
CO6270331A2 (es) 2011-04-20
MA31801B1 (fr) 2010-10-01
ATE512140T1 (de) 2011-06-15
RS53294B (sr) 2014-08-29
HRP20140346T1 (hr) 2014-05-09
MX2010005187A (es) 2010-05-27
SI2368887T1 (sl) 2014-05-30
EP2368887A1 (en) 2011-09-28
RS51918B (sr) 2012-02-29
US20100297054A1 (en) 2010-11-25
PT2368887E (pt) 2014-05-15
AU2008324172B2 (en) 2012-03-15
BRPI0820471A2 (pt) 2015-06-16
EA201070588A1 (ru) 2010-10-29
ZA201002596B (en) 2010-12-29
CY1115058T1 (el) 2016-12-14
SI2207770T1 (sl) 2011-09-30
ME01962B (en) 2012-02-29
CA2705113A1 (en) 2009-05-14
US8486977B2 (en) 2013-07-16
ES2366422T3 (es) 2011-10-20
KR101577080B1 (ko) 2015-12-11
HK1141528A1 (en) 2010-11-12
CN101918376B (zh) 2013-11-06
JP5491407B2 (ja) 2014-05-14
JP2011503031A (ja) 2011-01-27
PL2207770T3 (pl) 2011-10-31
EP2368887B8 (en) 2014-04-16
CY1112233T1 (el) 2015-12-09
EP2368887B1 (en) 2014-02-26
PT2207770E (pt) 2011-09-01
HRP20110552T1 (hr) 2011-09-30
EP2207770A1 (en) 2010-07-21
HK1160467A1 (en) 2012-08-17
ES2457521T3 (es) 2014-04-28
PL2368887T3 (pl) 2014-07-31
EA016621B1 (ru) 2012-06-29
WO2009060053A1 (en) 2009-05-14
NZ584725A (en) 2012-05-25
CR11482A (es) 2010-07-09
CN101918376A (zh) 2010-12-15
GB0722077D0 (en) 2007-12-19

Similar Documents

Publication Publication Date Title
DOP2010000137A (es) Derivados de 1,2,3-triazol como inhibidores de estearoil-coenzima a desaturasa
WO2008074824A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
WO2008074834A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
GEP20125487B (en) Organic compounds and their use
WO2008074832A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase ( scd)
ATE530524T1 (de) Substituierte sulfonamid-derivate
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2008074833A3 (en) Compounds
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
MX2011011080A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
TW200626158A (en) Naphthaline derivatives
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
TW200800993A (en) Organic compounds
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
GEP20125640B (en) Phenanthrenone compounds, compositions containing them and use thereof